US 12122773
Crystalline hydrate of a JAK inhibitor compound
granted A61KA61K9/0053A61P
Quick answer
US patent 12122773 (Crystalline hydrate of a JAK inhibitor compound) held by Theravance Biopharma R&D IP, LLC expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Theravance Biopharma R&D IP, LLC
- Grant date
- Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K9/0053, A61P, A61P11/00, A61P11/06